IFT80

Across TCGA pan-cancer cohorts, IFT80 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IFT80 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher IFT80 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated IFT80 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where IFT80 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.813	1.000	.004	16	view →
PDAC	DFS	Median	All	0.854	0.726	.008	11	view →
CCRCC	DFS	Median	All	1.000	0.064	.024	6	view →
LUAD	DFS	Median	III,IV	0.409	0.922	.024	3	view →
GBM	OS	Tertile	All	0.826	0.966	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IFT80–LSCC (DFS)

Open the LSCC breakdown →